fda indications for semaglutide approves first-ever oral GLP-1RA obesity and chronic weight management. Meet Wegovy (semaglutide) tablets. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults Novo's Wegovy adds another indication

Multiple studies have shown reductions in inflammatory markers among people taking GLP-1 agonists, and patients frequently report improvements in inflammation-related conditions

What to Expect in Month 1 Appetite changes: Noticeable suppression begins week 3-4 for most Mild nausea: 40% experience some nausea, usually mild Injection site reactions: Redness, itching, or mild pain at injection site (14% of patients) Fatigue: Some patients report low energy as body adjusts Bowel changes: Either constipation or looser stools as medication affects gut motility 4 Essential Strategies for Month 1 1

Wegovy is a shot you give yourself once a week

Regular Monitoring: Routine check-ins and testing ensure your body is responding well to semaglutide

Ozempic 0.25 mg 1 Prefilled pen 1.5 ml

aOR, adjusted odds ratio